You are here


Nexium (Esomeprazole) manufactured by AstraZeneca is a proton pump inhibitor approved by FDA in 2001 for the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. In late 2010, AstraZeneca announced a co-promotion agreement with Daiichi Sankyo to distribute Nexium.

The February 2016 issue of JAMA, Journal of the American Medical Association, included publication of new study results which showed a 20 to 50 percent increased risk of chronic kidney disease in patients taking Nexium (esomeprazole) and similar medications.

A 2009 study based in Copenhagen showed that PPI use may cause a rebound acid release if discontinued. This indicates that patients may become dependent on the medications.

In 2006, the medical journal, JAMA published a study which showed that long term use of PPI medications may increase the risk of hip fractures in the elderly. Nexium and other PPI medications have been the subject of investigations relating to harm since 2006.

Many Nexium lawsuits have been filed on behalf of consumers who have faced severe bone deterioration or fractures.

Serious complications faced till date

  • Chronic kidney disease
  • Nephritis
  • Renal Impairment
  • Bone Deterioration
  • Dementia/Seizures
  • Tetany(Muscle spasm)
  • Infections
  • Arrhythmia and Heart problems
  • Low magnesium level

Nexium Litigations

In 2010, PPI use was suspected of causing cardiac-related birth defects when taken during pregnancy. The Food and Drug Administration concluded that no statistically significant risk had been shown. In 2010, the FDA issued a consumer warning for bone deterioration with Nexium and other PPI use.

In 2011, the FDA issued an additional warning regarding the risk of the development of low magnesium levels or hypomagnesemia with symptoms of neurological, muscular and cardiac effects, when PPI medications such as Nexium are taken.

In December 2014, the FDA issued a warning about adding acute interstitial nephritis to the label, which when not treated may lead to renal failure.

Evidence to be looked for in potential cases

  • Usage of Nexium in Pharmacy records
  • Duration of Nexium usage
  • Indication for Nexium usage in Medical records
  • Complication and their Treatment after Nexium usage

Medical Record Review and claim validation of Nexium case should take approximately 4 hours in most instances; however, this approximation may vary in cases based on the volume of records.

or Contact Us for a Free Consultation!
Please fill out the details below, or e-mail us at Contact us for more info
Fields marked with '*' are mandatory.
Contact Number with Country code
Any additional information you would like to provide.
This selection is for testing whether you are a human visitor and to prevent automated spam submissions.
All fields are mandatory.